[Comparative study of effects of diltiazem, nifedipine and their combination on exercise stable angina].

Arch Mal Coeur Vaiss

Service de cardiologie A, CHU Timone, Marseille.

Published: February 1991

Diltiazem and Nifedipine could be synergic. The aim of this study was to investigate the benefits of their association. Eighteen patients, 15 men and 3 women, average age 61 +/- 6 years, with stable angina on effort, were studied. Eight patients had single vessel disease and 10 patients had multivessel disease. The patients underwent a randomised double-blind trial with 4 successive treatment periods each lasting one week: placebo; 360 mg/day of Diltiazem; 60 mg/day of Nifedipine; 180 mg/day of Diltiazem with 30 mg/day of Nifedipine. The benefits were evaluated clinically, by exercise stress testing and with drug plasma concentrations at the end of each sequence. The results at the end of the 3 treatment periods were significantly better than with placebo. Diltiazem was significantly better than Nifedipine with respect to the development of angina during exercise testing (1 patient compared with 7 patients) and to maximum load (118.3 +/- 33.3 watts compared with 105.9 +/- 35.4 watts) (p less than 0.05). The association of the two drugs did not give better results than Diltiazem alone. Compared with placebo, the total duration of exercise testing and the duration of 1 mm ST depression were significantly longer during the 3 treatment sequences but there were no significant differences between each of them. Secondary effects were significantly more common with Nifedipine (7 patients) and with the drug association (9 patients) than with Diltiazem alone (3 patients) or placebo (1 patient). Plasma concentrations of Diltiazem were 328 +/- 35 ng/l with the 360 mg/day dosage and 137 +/- 52 ng/l with the 180 mg/day dosage.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source

Publication Analysis

Top Keywords

diltiazem
8
diltiazem nifedipine
8
patients
8
disease patients
8
treatment periods
8
360 mg/day
8
mg/day diltiazem
8
diltiazem mg/day
8
mg/day nifedipine
8
180 mg/day
8

Similar Publications

Bariatric surgery and HIV: Joint venture between family, primary care, and HIV physicians.

J Family Med Prim Care

December 2024

Department of HIV and Blood Borne Viruses, Milton Keynes University Hospital, NHS Foundation Trust, Milton Keynes, UK.

We report a case of a 49-year-old female with a history of HIV infection for 12 years. The patient had excellent compliance with antiretroviral medications, raltegravir 400 mg twice daily and truvada once daily for HIV. Over the years, she maintained an undetectable viral load with a CD4+ count >200 cells/μL.

View Article and Find Full Text PDF

Pharmacokinetic Boosting of Calcineurin Inhibitors in Transplantation: Pros, Cons, and Perspectives.

Ther Drug Monit

February 2025

Service de Pharmacologie, Toxicologie et Pharmacovigilance, CHU Limoges, Limoges, France.

The concept of pharmacokinetic (PK) boosting of calcineurin inhibitors (CNI) emerged after the FDA approval of cyclosporine-A. Several studies followed, and the proof of concept was well established by the late 1990s. This also continued for the next blockbuster immunosuppressant, tacrolimus.

View Article and Find Full Text PDF

Metoprolol vs diltiazem for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis of adverse events.

Am J Emerg Med

December 2024

Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, MD, USA; Departments of Pharmacy and Emergency Medicine, University of Rochester Medical Center, Rochester, New York, USA. Electronic address:

Background: Intravenous (IV) diltiazem and metoprolol are commonly used to achieve rate control for atrial fibrillation with RVR (Afib with RVR), and are both recommended as first-line by current guidelines. While prior studies investigated the efficacy of these medications, there is little evidence available regarding the risk of adverse events (AEs) with their use.

Methods: We identified randomized controlled trials (RCT) and observational studies reporting rates of AEs following administration of IV diltiazem and metoprolol for Afib with RVR by searching PubMed, SCOPUS, EMBASE, and Cochrane Library.

View Article and Find Full Text PDF

Effects of antihypertensives with and without IL-6 lowering properties on long-term blood pressure control: The prospective HELIUS cohort.

Int J Cardiol Cardiovasc Risk Prev

March 2025

Department of Public and Occupational Health, Amsterdam Public health Research Institute, Amsterdam university Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

Article Synopsis
  • Chronic inflammation, particularly the role of interleukin-6 (IL-6), is being explored as a target for improving hypertension treatment.
  • In a study involving 1,510 participants over six years, it was found that calcium channel blockers (CCBs) with IL-6-lowering properties (specifically amlodipine and barnidipine) resulted in better blood pressure control compared to other CCBs.
  • No significant differences were seen in blood pressure control among other antihypertensive classes or across different ethnic groups, indicating a need for further research into IL-6's impact on hypertension management.
View Article and Find Full Text PDF

Looking at the albumin-drug binding via partitioning in aqueous two-phase system.

Biochem Biophys Res Commun

January 2025

Cleveland Diagnostics, 3615 Superior Ave., Cleveland, OH, 44114, USA. Electronic address:

The partition coefficient of human serum albumin (HSA) was analyzed in the PEG600-Dex70, 0.15 M NaCl/KCl in 0.01 M Na/K phosphate buffer, pH 7.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!